Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Digoxin”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,333 records · Page 74Linked to original sources

An update on digoxin.

This review deals briefly with recent developments in the therapeutic drug monitoring of digoxin. Strategies for decreasing the interference by digoxin metabolites, digoxin-like factors, and spironolactone metabolites in immunoassays of digoxin are discussed. Other issues addressed include the development of alternative methods of analysis, such as receptor assays and "high-pressure" liquid chromatography; digoxin-like factors in hypertension; drug-drug interactions; redistribution of digoxin stores in the body; and forensic considerations.

Digoxin↗

[Maternal concentration of serum digoxin and concentration in the amniotic fluid and neonatal serum].

Digoxin was assayed in maternal and neonatal sera and in the amniotic fluid in 14 pregnant patients chronically digitalized for mitral stenosis. Neonatal serum levels of digoxin are linearly correlated with maternal concentrations of the drug, and all are inversely related to maternal creatinine clearance. Amniotic fluid levels of the drug are not related to serum levels, but relate to amniotic fluid creatinine concentration. Fetal serum levels are identical to maternal ones for all practical purposes, but bear no relation to amniotic digoxin concentration. Digoxin was assayed with a commercial kit showing very little cross-reactivity with endogenous digoxin-like cross-reacting compounds. Pitfalls in commercial digoxin assays and clinical implications are discussed.

Amniotic Fluid↗

Reassessment of indications for digoxin. Are patients being withdrawn?

Several studies have shown that the majority of patients receiving digoxin can be successfully withdrawn. A medical record review was conducted to determine whether, in practice, patients were being withdrawn from digoxin. Original indications for digoxin therapy in 163 outpatients were as follows: congestive heart failure (CHF), 50%; supraventricular tachycardia (SVT), 23%; CHF and SVT, 10%; and unknown/unclear, 17%. One third of these patients were withdrawn during the 3.5-year study, and 79% remained stable, off digoxin. The most significant predictor of withdrawal was chart indication of reassessment of the need for digoxin. The majority of the patients (68%) were reassessed, and of these, almost half were withdrawn. Physicians appear to be reassessing the need for digoxin therapy, resulting in higher withdrawal rates than previously reported. Results suggest that patients with unclear original indications, a onetime indication, or without clinical evidence of CHF or SVT can be successfully withdrawn.

Aged↗

Increase in the cardiotonic action and in the therapeutic margin of digoxin by the adrenergic beta-stimulant doxaminol in cats.

The interaction between digoxin and the beta-sympathomimetic drug doxaminol was investigated in cats with acute heart failure induced by pentobarbital sodium. Doxaminol, 50 micrograms/kg X min, infused for 60 min caused a dose-dependent rise in dp/dtmax with little increase in heart rate. The maximum increase of 4.3 mHg/s was obtained after about 37 min. Digoxin, 10 micrograms/kg X min, and the combination of both drugs were infused until cardiac arrest. The maximum increase of dp/dtmax was observed after 29 min in both experiments; it was 5.7 mHg/s with digoxin alone and 7.3 mHg/s with the combination (p = 0.025). The combined infusion of epinephrine (0.3 micrograms/kg X min) plus digoxin (10 micrograms/kg X min) caused a maximal increase of dp/dtmax by 7.9 mHg/s. The cardiotoxic dose of digoxin was markedly reduced by epinephrine, not by doxaminol. The relevance of this difference to man cannot be assessed definitely because the ECG changes produced by digoxin in cats are different from those seen in man.

Animals↗

Lack of pharmacodynamic interactions between quinidine and digoxin in isolated atrial muscle of guinea pig heart.

Quinidine has been reported to have no effect on the positive inotropic action of digoxin observed in isolated cardiac muscle preparations. This is surprising because quinidine has been shown to reduce Na+ influx in cardiac muscle. The conditions which increase Na+ influx stimulate the glycoside binding to Na+- and K+-activated Mg++-dependent ATP phosphohydrolase (Na+,K+-ATPase), and therefore quinidine may be expected to have an opposite effect. Thus, the effects of quinidine on cardiac muscle and its possible interactions with digoxin were re-evaluated using electrically paced left atrial muscle preparations of guinea pig heart. Quinidine caused a frequency- and concentration-dependent decrease in maximal upstroke velocity and amplitude of the action potential without altering resting membrane potential. In addition, quinidine prolonged action potential duration markedly in a frequency-dependent manner. Despite action potential prolongation, the alkaloid reduced net Na+ influx as determined by a decrease in steady-state ouabain-sensitive 86Rb+ uptake. Under these conditions, however, quinidine failed to reduce the rate of onset or the maximal positive inotropic effect of digoxin; or did it reduce digoxin binding to Na+,K+- ATPase in beating atrial muscle preparations. Benzocaine, which reduced net Na+ influx without increasing the action potential duration, also failed to affect the peak inotropic effect of digoxin or the glycoside binding. Quinidine had no direct effects on glycoside binding to isolated cardiac Na+,K+-ATPase. Moreover, [3H]ouabain binding to isolated enzyme was relatively insensitive to changes in Na+ concentrations between 1 and 8 mM although binding was stimulated clearly by Na+ above 8 mM. These results indicate that quinidine, at therapeutic concentrations, does not interact pharmacodynamically with digoxin in isolated cardiac muscle.

Action Potentials↗

Improved liquid chromatographic/immunoassay of digoxin in serum.

This HPLC/immunoassay procedure measures digoxin in serum with no interference from digoxin metabolites or digoxin-like factors. We used solid-phase (C18 and Diol) extraction, a C18 column with a tetrahydrofuran/water mobile phase, and final quantification by fluorescence polarization immunoassay. Deslanoside and gitoxigenin were used as the internal standard and the retention-time marker, respectively. The average CV for 300-microL samples at digoxin concentrations between 0.9 and 3.9 nmol/L was 9.3%. Minimum column lifetime with daily use was three months. We also compared results, for 49 samples from patients taking digoxin, obtained with the Abbott "TDx FPIA digoxin I" and the present procedure. Discrepancies between the two methods were substantial for 20% of the samples.

Chromatography, High Pressure Liquid↗

[Anti-arrhythmia and arrhythmogenic actions of digoxin in ventricular rhythm disorders in patients with circulatory insufficiency].

Three-day ECG monitoring before and after digitalization of 55 patients with heart failure (HF) was performed. Digoxin did not make a considerable effect on the frequency of detection of high gradations of ventricular arrhythmias. Nevertheless it significantly reduced the mean number of ventricular extrasystoles (VES) per hour and the mean number of complex VES per hour in 8 (33.3%) patients out of 24 with frequent extrasystoles. A significant increase in the VES mean number per hour and in the complex VES mean number per hour was observed in 6 (25%) patients out of 24 with basal frequent extrasystoles. In patients with the antiarrhythmic effect of digoxin indices of the central hemodynamics (diastolic pressure in the pulmonary artery and ejection fraction) were significantly better and in patients with the arrhythmogenic effect of digoxin significantly worse in the absence of a significant difference between digoxin and K+ concentration in the plasma. Digoxin possessed a moderately pronounced antiarrhythmic effect mainly in the patients with HF early stages and in moderately pronounced disturbances of the central hemodynamics. In patients with severe manifestations of HF and with considerable deterioration of indices of the central hemodynamics digoxin in therapeutic concentrations can make an arrhythmogenic effect.

Adolescent↗

Solid-phase immunoassay of digoxin by measuring time-resolved fluorescence.

We describe a time-resolved fluoroimmunoassay for the cardiac glycoside digoxin. The assay depends on the competitive distribution of Eu3+-labeled anti-digoxin antibodies between solid-phase-bound digoxin and the digoxin in the sample or standard. After this immunoreaction, the bound fraction of the Eu3+-label is dissociated from the solid phase, converted into a highly fluorescent beta-diketone chelate, and measured in a fluorometer with time-resolution (1230 Arcus, LKB-Wallac). Sample volume is 20 microL, the incubation lasts 30 min, and the concentration range of the assay for digoxin is from 0.25 to 4.0 ng/mL (0.32-5.1 nmol of digoxin per liter). Correlation with an in-house RIA was good (r = 0.97, n = 43). The sensitivity was equivalent to that of most RIAs: 0.2 ng/mL (0.25 nmol/L).

Antibodies↗

[Determination of digoxin in serum. Comparison of radioimmunoassay and a heterogeneous enzyme immunoassay (author's transl)].

This paper describes the evaluation of a heterogeneous enzymeimmunoassay (EIA, subtype ELISA) for the determination of digoxin in serum. Results are compared with those obtained from a radioimmunoassay (New England Nuclear, 125I-Digoxin). The limit of detection is 0.3 microgram/1 (0.4 nmol/1). The range of the test is from 0.3 unto 5.0 microgram/1 (0.4--6.4 nmol/1). Within-batch precision ranged from 7 to 11%, between-batch precision from 8--14%. Pure digoxin, added to solutions of albumin and pooled sera, gave recoveries between 87 and 106%. 116 sera from patients taking digoxin exclusively yielded no systematic difference compared to the results of a radioimmunoassay (RIA) (equation of the bivariate regression CELISA = 0.954 . CRIA + 0.14 (microgram/1) (0.18 nmol/1). Nevertheless marked differences between both tests were observed in individual cases. Digitoxin yielded in vitro and in vivo a cross-reactivity of 7 to 14% depending upon the concentration. In 68 sera from patients, taking digoxin plus spironolactone, we found results that were on average 0.48 microgram/1 (0.64 nmol/1) higher with the ELISA than with the RIA (p less than 0.01%). With respect to practicability the ELISA test for digoxin is very similar to the analogous RIA both using the solid phase technique.

Cross Reactions↗

Non-interaction between nifedipine and digoxin.

In order to evaluate a possible interaction between digoxin and nifedipine, we studied steady state digoxin pharmacokinetics before and during oral coadministration of nifedipine in eight healthy subjects. Mean plasma digoxin concentration was 0.68 +/- 0.15 ng/ml during control conditions versus 0.74 +/- 0.13 ng/ml (NS) after two weeks of nifedipine coadministration. Nifedipine caused no significant changes in either renal digoxin clearance (173.6 +/- 25.9 versus 173.1 +/- 33.2 ml/min) or 24-hour urinary recovery of digoxin (164.7 +/- 25.7 versus 183.8 +/- 29.2 micrograms/24 hrs). Our findings support earlier observations that nifedipine coadministration is not associated with any significant alteration of digoxin pharmacokinetics.

Adult↗

Comparison of the serum protein binding of digoxin in premature and mature newborns, infants and adults.

Infants require higher therapeutic doses (per unit body weight and surface area) and also tolerate higher doses of digoxin than adults. In contrast premature and even mature newborns are more susceptible to digoxin intoxications. Serum protein binding contributes to the apparent volume of distribution. Since the volume of distribution for digoxin shows an age-dependency, the present study was designed to determine the plasma protein binding of digoxin in premature and mature newborns as well as in infants and adults. Using the equilibrium dialysis method the fraction of digoxin bound to serum protein averages 30% in all groups studied. Thus protein binding could not account for the differences in dosage and susceptibility of digoxin in newborns and infants as compared to adults.

Adult↗

Plasma and tissue levels of digoxin in the rat following pretreatment with verapamil.

Verapamil and digoxin are frequently used in combination, and clinical experience suggests that verapamil may increase digoxin toxicity. We have investigated the influence of verapamil on digoxin pharmacokinetics in the rat. Rats were injected with 10 mg/kg verapamil s.c. twice a day for 7 days while control rats were injected with saline only. On the 7th day, all the rats received 0.5 mg/kg of digoxin i.p. Two, 4, 6, 8 and 10 hours later, groups of 6 to 8 verapamil pretreated and control animals were sacrificed and plasma, heart, brain, liver, kidney and muscle digoxin concentrations were assayed. Digoxin levels were significantly higher in the plasma, heart, liver and muscle of the verapamil pretreated rats at 6, 8 and 10 hours (p less than 0.01).

Animals↗

Digoxin treatment and control in the elderly.

The efficacy and the risk of toxicity of long-term digoxin therapy were assessed in 81 elderly patients. The findings show that the serum digoxin level did not correlate with the clinical state. Only 47% of the patients were on a dosage considered to be effective by serum digoxin analysis, whereas 38% of the patients had levels below the therapeutic range; 51% of the patients had been treated with pediatric or semipediatric doses only. Electrocardiographic evidence of digoxin toxicity was found in 17%. Routine periodic measurement of serum digoxin did not correlate with better management. The optimum dosage of digoxin in the elderly patient who is not in overt renal failure and who is not particularly underweight would seem to be 0.19 mg/day, i.e., one and one-half tablets of 0.25 mg on alternate days.

Aged↗

[Results of a double blind study with segontin--digoxin in coronary heart disease. (author's transl)].

Segontin-Digoxin and digoxin were tested in a cross-over double blind trial in 30 patients with coronary heart disease and concomitant organic insufficiency in a cardiological specialist practice. As far as the coronary symptoms were concerned, treatment with Segontin-Digoxin was clearly superior to digoxin therapy alone. With regard to the elimination or improvement of signs of myocardial insufficiency, no difference could be established between the two preparations. A distinct lowering of heart rate and blood pressure, especially in hypertensives, was observed with Segontin-Digoxin therapy compared with digoxin alone.

Adult↗

[Results of a double blind study with Segontin-Digoxin in coronary heart disease (author's transl)].

Segontin-Digoxin and digoxin were tested in a cross-over double blind trial in 30 patients with coronary heart disease and concomitant organic insufficiency in a cardiological specialist practice. As far as the coronary symptoms were concerned, treatment with Segontin-Digoxin was clearly superior to digoxin therapy alone. With regard to the elimination or improvement of signs of myocardial insufficiency, no difference could be established between the two preparations. A distinct lowering of heart rate and blood pressure, especially in hypertensives, was observed with Segontin-Digoxin therapy compared with digoxin alone.

Adult↗

Multiple-dose kinetics of digoxin in neonates.

Multiple-dose kinetics of digoxin were studied over a 7-day period in five neonates receiving intravenous digoxin therapy (one initial digitalizing dose followed by single daily doses). Their weights ranged from 1.04 to 2.68 kg (means = 1.61 kg), gestational ages from 28 to 39 weeks (means = 31.8 weeks), and postnatal ages from 2 to 19 days (means = 8.0 days). The 24-hour serum digoxin levels and urinary creatinine and digoxin excretion after the 1st and 7th doses on days 1 and 7 were employed to derive the kinetic parameters. Values of each following parameter (mean +/- SD) were obtained on days 1 and 7, respectively: (1) creatinine clearance (ml/min/1.73 m2) 12 +/- 6, 13 +/- 8; (2) renal digoxin clearance (ml/min/1.73 m2) 13 +/- 8, 15 +/- 10; (3) total body digoxin clearance (ml/min/1.73 m2) 35 +/- 14, 39 +/- 24; (4) volume of distribution (L/kg) 7.2 +/- 1.0, 6.9 +/- 1.1; and (5) half-life (hours) 48 +/- 19, 49 +/- 27. No consistent changes of the above kinetic parameters from days 1 to 7 were observed in these five neonates (P greater than 0.05, paired student's t-test).

Birth Weight↗

[Clinical study on digoxin tablets with high bioavailability (author's transl)].

The relationship between different maintenance doses and the steady-state digoxin blood concentration was studied in 160 patients with heart failure. All patients received digoxin tablets of the same brand (Digacin). The bioavailability of this brand is 82% compared with an i.v. standard. During the treatment with daily doses of 0.2 mg and 0.3 mg average serum digoxin levels of 1.09 +/- 0.45 ng/ml and 1.33 +/- 0.53 ng/ml were measured in patients with normal renal function. The daily dose of 0.4 mg digoxin was in correlation to an average serum level of 1.75 +/- 0.81 ng/ml. 81% and 86% of all patients with normal renal function taking 0.2 or 0.3 mg digoxin every day were found to have levels in the range of 0.7 to 2.0 ng/ml. The influence of sex, age, height, body weight, maintenance dose, serum creatinine and serum potassium on the variance of the digoxin plasma levels was computed by multiple linear regression. The multiple correlation coefficient was r = 0.666, the coefficient of determination (100 r2) being 44.4%. Therefore 44.4% of the total variance could be explained by these variables. Individual variables accounted for the following percentages of the total variance: serum creatinine 29.1%; maintenance dose 14.5%; age 4.3%; and reciprocal of body weight 3.9%.

Aging↗

[The therapeutical profit of encymatic analysis of serum digoxin on geriatric patients (author's transl)].

The develpment of an encymimmunological method of analysis for serum digoxin level makes it possible to analyse serum digoxin in hospital as well as in practice. The therapeutical profit of this encymimmunological method was tested with 32 patients being digitalised because of having a cardiac insufficiency besides various diseases and different degree of disablement. The therapeutical profit should be an extended individual radius of action. There are compared two periods of therapy. In the first way the level of serum digoxin was unknown and in the second way the level of serum digoxin was known and taken into consideration by the medical treatment. The dose of digitalis was fixed under consideration of all clinical symptoms and not only under consideration of the level of serum digoxin. That the method of analysis of serum digoxin is useful was demonstrated by a sixth part of the patients, where a wrong assessment of clinical symptoms turned out and could be corrected. The clinical symptomatic of overdigitalisation was easier to recognise and less necessary to be changed than underdigitalisation.

Aged↗